Ensuring Access to Optimal Therapy in CF: The ENACT Study
Status:
RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).
Phase:
PHASE4
Details
Lead Sponsor:
Arkansas Children's Hospital Research Institute
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)
Treatments:
elexacaftor, ivacaftor, tezacaftor drug combination tezacaftor, ivacaftor drug combination